Allergan Unlimited Company, formerly Allergan Limited, is an Ireland-based pharmaceutical company. The Company is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. The Company's products primarily focus on four key therapeutic areas, including medical aesthetics, eye care, central nervous system and gastroenterology.

Employees

Sector

Pharmaceuticals

More about the company

Delayed NYSE			5-day change	1st Jan Change
- ^USD	-.--%		+1.73%	+0.97%

04-07	Allergan Aesthetics Opens New Ami Training Center in Austin	CI
03-31	Allergan Aesthetics Announces Fourth Annual CoolMonth With Deals On CoolSculpting	CI

Market Cap	63.66B 54.64B 51.16B 46.85B 88.25B 6,080B 88.5B 606B 237B 3,064B 239B 234B 10,141B	P/E 2018	-8.76x	P/E 2019	-11.9x
Enterprise Value	80.96B 69.5B 65.07B 59.58B 112B 7,733B 113B 770B 301B 3,897B 304B 297B 12,898B	EV / Sales 2018	4.24x	EV / Sales 2019	4.98x
Free-Float	99.9%	Yield 2018	2.15%	Yield 2019	1.55%

04-07	Allergan Aesthetics Opens New Ami Training Center in Austin	CI
03-31	Allergan Aesthetics Announces Fourth Annual CoolMonth With Deals On CoolSculpting	CI
03-30	Allergan Aesthetics Presents Findings on Safety and Efficacy of Repeat Trenibote Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors At the 2026 American Academy of Dermatology Meeting	CI
03-19	Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions	CI
03-04	Allergan Aesthetics Shares Medical Weight Loss Data and the Changing Profile of Patients	CI
11-12	Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence	CI
25-09-25	AllAllergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality At AMWC Dubai	CI
25-08-19	Allergan Aesthetics Unveils Its Newest Hydration Hero	CI
25-06-30	U.S. Food and Drug Administration Accepts for Review Allergan Aesthetics Premarket Approval Application for Skinvive by Juvederm for the Improvement of Neck Appearance	CI
25-02-12	Allergan Aesthetics to Launch Three New Training Centers in the U.S. Expanding Access to High Quality Aesthetics Training	CI
24-10-18	BOTOX® Cosmetic (onabotulinumtoxinA) Receives FDA Approval for Moderate to Severe Vertical Bands Connecting the Jaw and Neck (Platysma Bands)	CI
24-08-27	Allergan Aesthetics Announces the Launch of Its Next Generation Hydration Product: Skinmedica HA5 Hydra Collagen Replenish + Restore Hydrator	CI
24-06-27	Allergan Aesthetics Debuts Alle Payment Plans	CI

24-04-01	Court Dismisses Class Action Against Biopharmaceutical Company For Failing To Disclose Progress Of Competitor; Second Circuit Affirms Dismissal Of Putative Class Action Against Allergan; Eleventh Circuit Affirms That "Toxic" Lender Qualified As A "Dealer" Under The Exchange Act Due To High-Volume Trading; Delaware Court Of Chancery Invalidates Governance Rights In Stockholder Agreement	AQ
22-04-20	Allergan, an AbbVie Company, to Present New Data from its Eye Care Portfolio at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting	AQ
22-04-06	Allergan, an AbbVie Company, Announces Positive Topline Phase 3 Results Evaluating Investigational Twice-Daily Administration of VUITY 1.25% in Adults with Age-Related Blurry Near Vision	AQ
22-03-22	AbbVie and Allergan Aesthetics to Present New Research Across Dermatology Portfolio at 2022 AAD Annual Meeting	AQ
21-12-10	Allergan - VUITY 1.25%, the First and Only FDA-Approved Eye Drop to Treat Age-Related Blurry near Vision, is Now Available	AQ

Allergan plc Stock

Stocks

AGN

IE00BY9D5467

Pharmaceuticals

Valuation : Allergan plc

Latest news : Allergan plc

Press Releases : Allergan plc

News in other languages : Allergan plc

Managers and Directors : Allergan plc

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

21-04-20	Planète Bourse : La revue de presse du mardi 20 avril 2021
20-05-07	EN DIRECT DES MARCHES : Air France KLM, ArcelorMittal, Legrand, Natixis, Peugeot, Eurofins, Zalando, Facebook...
20-05-07	La Chine repart, mais Washington veille
20-05-06	EN DIRECT DES MARCHES : Danone, Sanofi, Crédit Agricole, Arkema, Neoen, Eurofins, BMW, Novo Nordisk...
20-05-06	Trump franchit le Rubicon

Manager	Title	Age	Since
Alex Thurman DFI	Director of Finance/CFO	56	2016-11-30
Robert Michael PSD	President	55	2020-05-07

Director	Title	Age	Since
Robert Michael BRD	Director/Board Member	55	2020-05-07
Scott Reents BRD	Director/Board Member	-	2020-05-07
Ryan Quigley BRD	Director/Board Member	-	2020-05-07

Date	Insider	Type	Main position	Quantity	% Market Cap.
5/8/20	James D'Arecca	Issuer sale	Controller/Auditor	19,495	0.0059%
5/8/20	Adriane Brown	Issuer sale	Director	2,916	0.0009%
5/8/20	Matthew Walsh	Issuer sale	Chief Financial Officer	67,678	0.0206%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALLERGAN PLC	-.--%	+1.73%	-	-	63.66B
ELI LILLY AND COMPANY	-1.12%	-5.49%	+60.19%	+112.43%	1,048B
JOHNSON & JOHNSON	-1.57%	-0.60%	+50.33%	+59.86%	640B
ABBVIE INC.	-1.81%	-1.41%	+24.07%	+75.98%	456B
ROCHE HOLDING AG	-0.70%	-3.73%	+38.54%	+39.53%	362B
NOVARTIS AG	-0.16%	-2.29%	+22.61%	+37.63%	295B
ASTRAZENECA PLC	-0.37%	+0.41%	+1.92%	+12.00%	255B
AMGEN INC.	-0.76%	+0.75%	+51.75%	+70.45%	236B
NOVO NORDISK A/S	+0.82%	-1.08%	-17.06%	-53.97%	204B
GILEAD SCIENCES, INC.	+0.52%	+3.78%	+30.67%	+93.68%	185B
Average	+0.11%	-0.48%	+29.23%	+49.73%	374.53B
Weighted average by Cap.	+0.35%	-1.86%	+38.53%	+65.81%

	2018	2019
Net sales	15.79B 13.55B 12.69B 11.62B 21.89B 1,508B 21.95B 150B 58.73B 760B 59.27B 57.99B 2,515B	16.09B 13.81B 12.93B 11.84B 22.3B 1,537B 22.37B 153B 59.85B 774B 60.41B 59.1B 2,563B
Net income	-5.1B -4.37B -4.1B -3.75B -7.06B -487B -7.09B -48.5B -18.96B -245B -19.13B -18.72B -812B	-5.27B -4.52B -4.24B -3.88B -7.31B -503B -7.33B -50.16B -19.61B -254B -19.79B -19.36B -840B
Net Debt	21.89B 18.79B 17.59B 16.11B 30.35B 2,091B 30.43B 208B 81.43B 1,054B 82.19B 80.41B 3,487B	17.3B 14.85B 13.91B 12.73B 23.99B 1,653B 24.06B 165B 64.37B 833B 64.97B 63.57B 2,757B